Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$2.11 – $2.70
4% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $344.53B | $425.27B | $456.41B | $521.05B | $552.15B | $596.57B | $584.51B | $560.33B |
| Cost of revenue | $313.30B | $387.74B | $416.09B | $477.00B | $504.71B | $548.06B | $540.25B | $520.17B |
| Gross profit | $31.23B | $37.53B | $40.32B | $44.05B | $47.43B | $48.51B | $44.26B | $40.15B |
| Gross margin | 9.1% | 8.8% | 8.8% | 8.5% | 8.6% | 8.1% | 7.6% | 7.2% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $15.40B | $16.14B | $17.76B | $19.71B | $20.60B | $20.21B | $16.19B | $16.24B |
| EBITDA | $16.67B | $20.32B | $22.62B | $24.68B | $26.25B | $26.90B | $20.17B | $20.41B |
| Net income | $9.40B | $10.62B | $7.19B | $7.76B | $8.53B | $9.05B | $7.05B | $6.97B |
| Net margin | 2.7% | 2.5% | 1.6% | 1.5% | 1.5% | 1.5% | 1.2% | 1.2% |
| EPS (diluted) | 3.16 | 3.57 | 2.31 | 2.49 | 2.73 | 2.90 | 2.26 | 2.24 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $609.2B | $2.50 | $2.35–$2.63 | 1 |
| 2027 | $637.3B | $2.71 | $2.54–$2.85 | 1 |
| 2028 | $669.9B | $2.96 | $2.78–$3.12 | 1 |
Forward consensus · source: Financial Modeling Prep
SINOPHARM GROUP CO LTD
No one on the platform currently holds SHTDF.
No tracked institution reports a position in SHTDF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-25 | $0.7900 | 2026-08-18 |
| 2025-06-18 | $0.7390 | 2025-08-12 |
| 2024-06-18 | $0.9560 | 2024-08-13 |
No one on the platform has traded SHTDF yet.
| +0.00% |
| $6.2B |
| — |
| MSMKFMatsukiyoCocokara & Co. | $14.60 | +0.00% | $5.7B | — |
| SHPMFShanghai Pharmaceuticals Holding Co., Ltd | $1.46 | +0.00% | $8.5B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.4× earnings vs its 1.0× historical median P/E.
Fair value ≈ $5.50 · price $2.13 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.